PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer
PMV Pharmaceuticals PYNNACLE Phase I Data Of Rezatapopt In Advanced Ovarian Cancer Featured In Oral Presentation At 2024 SGO Annual Meeting On Women's Cancer
PMV Pharmicals PYNACLE PYNACLE 在晚期卵巢癌領域的 Rezatapopt I 期數據已在 2024 年 SGO 女性癌症年會上口頭陳述
-
Phase 1 analysis from the PYNNACLE Phase 1/2 study showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation featured in a late-breaking oral presentation at 2024 SGO Annual Meeting
-
Of the 15 patients in the efficacy evaluable population, seven patients achieved a confirmed partial response with a seven-month median duration of response and a favorable safety profile
- Rezatapopt is a first-in-class precision oncology investigational therapy in patients with advanced solid tumors with a TP53 Y220C mutation and KRAS wild-type which is being evaluated in a registrational Phase 2 study
-
PYNNACLE 1/2期研究的1期分析顯示，rezatapopt（PC14586）在經過大量預治療且攜帶TP53 Y220C 突變的晚期卵巢癌患者中具有可觀的療效，該患者在2024年SGO年會上發表的最新口頭陳述中有所介紹
-
在療效可評估人群中的15名患者中，有7名患者獲得了證實的部分緩解，中位緩解持續時間爲七個月，安全性良好
- Rezatapopt 是首款針對具有 TP53 Y220C 突變和 KRAS 野生型的晚期實體瘤患者的精準腫瘤研究療法，該療法正在一項註冊性 2 期研究中進行評估